Literature DB >> 22918081

Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421.

M M O'Brien, X Cao, S Pounds, G V Dahl, S C Raimondi, N J Lacayo, J Taub, M Chang, H J Weinstein, Y Ravindranath, H Inaba, D Campana, C H Pui, J E Rubnitz.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22918081      PMCID： PMC4577013          DOI： 10.1038/leu.2012.223

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Nineteen cases of the t(1;22)(p13;q13) acute megakaryblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group.

Authors:  J Bernstein; N Dastugue; O A Haas; J Harbott; N A Heerema; J L Huret; J Landman-Parker; M M LeBeau; C Leonard; G Mann; M P Pages; C Perot; H Pirc-Danoewinata; B Roitzheim; C M Rubin; M Slociak; F Viguie
Journal:  Leukemia       Date:  2000-01       Impact factor: 11.528

2.  Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment.

Authors:  D Reinhardt; S Diekamp; C Langebrake; J Ritter; J Stary; M Dworzak; A Schrauder; M Zimmermann; G Fleischhack; W-D Ludwig; J Harbott; U Creutzig
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

3.  Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia.

Authors:  Z Ma; S W Morris; V Valentine; M Li; J A Herbrick; X Cui; D Bouman; Y Li; P K Mehta; D Nizetic; Y Kaneko; G C Chan; L C Chan; J Squire; S W Scherer; J K Hitzler
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

4.  The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children.

Authors:  T Lion; O A Haas; J Harbott; E Bannier; J Ritterbach; M Jankovic; F M Fink; A Stojimirovic; J Herrmann; H J Riehm
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

5.  Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.

Authors:  David Becton; Gary V Dahl; Yaddanapudi Ravindranath; Myron N Chang; Fred G Behm; Susana C Raimondi; David R Head; Kimo C Stine; Norman J Lacayo; Branimir Ivan Sikic; Robert J Arceci; Howard Weinstein
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

6.  Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

Authors:  Ursula Creutzig; Martin Zimmermann; Thomas Lehrnbecher; Norbert Graf; Johann Hermann; Charlotte M Niemeyer; Alfred Reiter; Jörg Ritter; Michael Dworzak; Jan Stary; Dirk Reinhardt
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

7.  Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.

Authors:  Dorothy R Barnard; Todd A Alonzo; Robert B Gerbing; Beverly Lange; William G Woods
Journal:  Pediatr Blood Cancer       Date:  2007-07       Impact factor: 3.167

8.  Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.

Authors:  V H J van der Velden; A van der Sluijs-Geling; B E S Gibson; J G te Marvelde; P G Hoogeveen; W C J Hop; K Wheatley; M B Bierings; G J Schuurhuis; S S N de Graaf; E R van Wering; J J M van Dongen
Journal:  Leukemia       Date:  2010-07-29       Impact factor: 11.528

9.  CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome.

Authors:  Süreyya Savaşan; Steven Buck; Susana C Raimondi; David L Becton; Howard Weinstein; Myron Chang; Yaddanapudi Ravindranath
Journal:  Leuk Lymphoma       Date:  2006-10

10.  Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Français d'Hématologie Cellulaire (GFHC).

Authors:  Eliane Duchayne; Odile Fenneteau; Marie-Pierre Pages; Danielle Sainty; Christine Arnoulet; Nicole Dastugue; Richard Garand; Georges Flandrin
Journal:  Leuk Lymphoma       Date:  2003-01
View more
  19 in total

Review 1.  Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.

Authors:  Kelly Faulk; Lia Gore; Todd Cooper
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

Review 2.  Prognosis and management of acute myeloid leukemia in patients with Down syndrome.

Authors:  J Timothy Caldwell; Yubin Ge; Jeffrey W Taub
Journal:  Expert Rev Hematol       Date:  2014-09-18       Impact factor: 2.929

Review 3.  The genomics of acute myeloid leukemia in children.

Authors:  Shannon E Conneely; Rachel E Rau
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

4.  AMKL chimeric transcription factors are potent inducers of leukemia.

Authors:  J Dang; S Nance; J Ma; J Cheng; M P Walsh; P Vogel; J Easton; G Song; M Rusch; A L Gedman; C Koss; J R Downing; T A Gruber
Journal:  Leukemia       Date:  2017-02-08       Impact factor: 11.528

5.  Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study.

Authors:  Hiroto Inaba; Yinmei Zhou; Oussama Abla; Souichi Adachi; Anne Auvrignon; H Berna Beverloo; Eveline de Bont; Tai-Tsung Chang; Ursula Creutzig; Michael Dworzak; Sarah Elitzur; Alcira Fynn; Erik Forestier; Henrik Hasle; Der-Cherng Liang; Vincent Lee; Franco Locatelli; Riccardo Masetti; Barbara De Moerloose; Dirk Reinhardt; Laura Rodriguez; Nadine Van Roy; Shuhong Shen; Takashi Taga; Daisuke Tomizawa; Allen E J Yeoh; Martin Zimmermann; Susana C Raimondi
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

6.  Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia.

Authors:  Diane S Krause; John D Crispino
Journal:  Clin Cancer Res       Date:  2013-08-20       Impact factor: 12.531

Review 7.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

Authors:  C Michel Zwaan; Edward A Kolb; Dirk Reinhardt; Jonas Abrahamsson; Souichi Adachi; Richard Aplenc; Eveline S J M De Bont; Barbara De Moerloose; Michael Dworzak; Brenda E S Gibson; Henrik Hasle; Guy Leverger; Franco Locatelli; Christine Ragu; Raul C Ribeiro; Carmelo Rizzari; Jeffrey E Rubnitz; Owen P Smith; Lillian Sung; Daisuke Tomizawa; Marry M van den Heuvel-Eibrink; Ursula Creutzig; Gertjan J L Kaspers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

8.  Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes.

Authors:  Sébastien Malinge; Tim Chlon; Louis C Doré; Rhett P Ketterling; Martin S Tallman; Elisabeth Paietta; Alan S Gamis; Jeffrey W Taub; Stella T Chou; Mitchell J Weiss; John D Crispino; Maria E Figueroa
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

9.  Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.

Authors:  Seth E Karol; Elaine Coustan-Smith; Xueyuan Cao; Sheila A Shurtleff; Susana C Raimondi; John K Choi; Raul C Ribeiro; Gary V Dahl; William Paul Bowman; Jeffrey W Taub; Barbara Degar; Wing Leung; James R Downing; Ching-Hon Pui; Jeffrey E Rubnitz; Dario Campana; Hiroto Inaba
Journal:  Br J Haematol       Date:  2014-08-28       Impact factor: 6.998

10.  Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study.

Authors:  Jasmijn D E de Rooij; Riccardo Masetti; Marry M van den Heuvel-Eibrink; Jean-Michel Cayuela; Jan Trka; Dirk Reinhardt; Mareike Rasche; Edwin Sonneveld; Todd A Alonzo; Maarten Fornerod; Martin Zimmermann; Martina Pigazzi; Rob Pieters; Soheil Meshinchi; C Michel Zwaan; Franco Locatelli
Journal:  Blood       Date:  2016-04-25       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.